
[Federal Register Volume 80, Number 70 (Monday, April 13, 2015)]
[Notices]
[Pages 19671-19672]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: 2015-08362]


-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration

[Docket No. FDA-2013-E-0475]


Determination of Regulatory Review Period for Purposes of Patent 
Extension; ELVITEGRAVIR

AGENCY: Food and Drug Administration, HHS.

ACTION: Notice.

-----------------------------------------------------------------------

SUMMARY: The Food and Drug Administration (FDA) has determined the 
regulatory review period for ELVITEGRAVIR (as a component of STRIBILD) 
and is publishing this notice of that determination as required by law. 
FDA has made the determination because of the submission of an 
application to the Director of the U.S. Patent and Trademark Office 
(USPTO), Department of Commerce, for the extension of a patent which 
claims that human drug product.

ADDRESSES: Submit electronic comments to http://www.regulations.gov. 
Submit written petitions (two copies are required) and written comments 
to the Division of Dockets Management (HFA-305), Food and Drug 
Administration, 5630 Fishers Lane, Rm. 1061, Rockville, MD 20852. 
Submit petitions electronically to http://www.regulations.gov at Docket 
No. FDA-2013-S-0610.

FOR FURTHER INFORMATION CONTACT: Beverly Friedman, Office of 
Management, Food and Drug Administration, 10001 New Hampshire Ave., 
Hillandale Campus, Rm. 3180, Silver Spring, MD 20993, 301-796-7900.

SUPPLEMENTARY INFORMATION: The Drug Price Competition and Patent Term 
Restoration Act of 1984 (Pub. L. 98-417) and the Generic Animal Drug 
and Patent Term Restoration Act (Pub. L. 100-670) generally provide 
that a patent may be extended for a period of up to 5 years so long as 
the patented item (human drug product, animal drug product, medical 
device, food additive, or color additive) was subject to regulatory 
review by FDA before the item was marketed. Under these acts, a 
product's regulatory review period forms the basis for determining the 
amount of extension an applicant may receive.
    A regulatory review period consists of two periods of time: A 
testing phase and an approval phase. For human drug products, the 
testing phase begins when the exemption to permit the clinical 
investigations of the drug becomes effective and runs until the 
approval phase begins. The approval phase starts with the initial 
submission of an application to market the human drug product and 
continues until FDA grants permission to market the drug product. 
Although only a portion of a regulatory review period may count toward 
the actual amount of extension that the Director of USPTO may award 
(for example, half the testing phase must be subtracted as well as any 
time that may have occurred before the patent was issued), FDA's 
determination of the length of a regulatory review period for a human 
drug product will include all of the testing phase and approval phase 
as specified in 35 U.S.C. 156(g)(1)(B).
    FDA has approved for marketing the human drug product ELVITEGRAVIR 
(as a component of STRIBILD (cobicistat/emtricitabine/ELVITEGRAVIR/
tenofovir disoproxil fumarate)). STRIBILD is indicated as a complete 
regimen for the treatment of HIV-1 infection in adults who are 
antiretroviral treatment-naive. Subsequent to this approval, the USPTO 
received a patent term restoration application for ELVITEGRAVIR (as a 
component of STRIBILD) (U.S. Patent No. 7,176,220) from Japan Tobacco 
Inc., and the USPTO requested FDA's assistance in determining this 
patent's eligibility for patent term restoration. In a letter dated 
July 10, 2013, FDA advised the USPTO that this human drug product had 
undergone a regulatory review period and that the approval of STRIBILD 
represented the first permitted commercial marketing or use of the 
ELVITEGRAVIR product. Thereafter, the USPTO requested that FDA 
determine the product's regulatory review period.
    FDA has determined that the applicable regulatory review period for 
ELVITEGRAVIR (as a component of STRIBILD) is 2,666 days. Of this time, 
2,360 days occurred during the testing phase of the regulatory review 
period, while 306 days occurred during the approval phase. These 
periods of time were derived from the following dates:
    1. The date an exemption under section 505(i) of the Federal Food, 
Drug, and Cosmetic Act (the FD&C Act) (21 U.S.C. 355(i)) became 
effective: May 12, 2005. The applicant claims May 18, 2005, as the date 
the investigational new drug application (IND) for ELVITEGRAVIR became 
effective. However, FDA records indicate that the IND effective date 
was May 12, 2005, which was the date the IND sponsor was notified that 
clinical trials may proceed.
    2. The date the application was initially submitted with respect to 
the human drug product under section 505(b) of the FD&C Act: October 
27, 2011. The applicant claims October 26, 2011, as the date the new 
drug application (NDA) for STRIBILD (NDA 203-100) was initially 
submitted. However, FDA records indicate that NDA 203-100 was submitted 
on October 27, 2011.
    3. The date the application was approved: August 27, 2012. FDA has 
verified the applicant's claim that NDA 203-100 was approved on August 
27, 2012.
    This determination of the regulatory review period establishes the 
maximum potential length of a patent extension. However, the USPTO 
applies several statutory limitations in its calculations of the actual 
period for patent extension. In its application for patent extension, 
this applicant seeks 1,021 days of patent term extension.
    Anyone with knowledge that any of the dates as published are 
incorrect may submit to the Division of Dockets Management (see 
ADDRESSES) either electronic or written comments and ask for a 
redetermination by June 12, 2015. Furthermore, any interested person 
may petition FDA for a determination regarding whether the applicant 
for extension acted with due diligence during the regulatory review 
period by October 13, 2015. To meet its burden, the petition must 
contain sufficient facts to merit an FDA investigation. (See H. Rept. 
857, part 1, 98th Cong., 2d sess., pp. 41-42, 1984.) Petitions should 
be in the format specified in 21 CFR 10.30.
    Interested persons may submit to the Division of Dockets Management 
(see ADDRESSES) electronic or written comments and written or 
electronic

[[Page 19672]]

petitions. It is only necessary to send one set of comments. Identify 
comments with the docket number found in brackets in the heading of 
this document. If you submit a written petition, two copies are 
required. A petition submitted electronically must be submitted to 
http://www.regulations.gov, Docket No. FDA-2013-S-0610. Comments and 
petitions that have not been made publicly available on http://www.regulations.gov may be viewed in the Division of Dockets Management 
between 9 a.m. and 4 p.m., Monday through Friday.

    Dated: April 7, 2015.
Leslie Kux,
Associate Commissioner for Policy.
[FR Doc. 2015-08362 Filed 4-10-15; 8:45 am]
 BILLING CODE 4164-01-P


